The "STARHB" was launched in June 2022 by the China Liver Health, led by Professor Chen Xinyue of Beijing You'an Hospital affiliated to Capital Medical University and Professor Gao Zhiliang of the Third Affiliated Hospital of Sun Yat sen University.  By the end of September 2022,42base hospitals and 298 sub central hospitals have been set up, totaling 340, covering 28 provinces, cities and autonomous regions in China. Among them, as of June 21, the first batch of 38 base hospitals and 223 sub center hospitals had passed the application; As of August 26, the second batch of 4 base hospitals and 75 branch hospitals had passed the application.
"STARHB"is the first large-scale public welfare project targeting inactive HBeAg negative chronic HBV infected persons (referred to as IHC population) in China, aiming to help more chronic hepatitis B infected persons get clinical cure, and strive to achieve the goal of "Healthy China 2030" and the World Health Organization 2030 to eliminate the public health hazards of viral hepatitis. Inactive HBeAg negative chronic HBV infected people are often clinically neglected hepatitis B infected people, and many research data show that the long-term prognosis of such people is not safe, and they have a higher chance of clinical cure. How to grasp the best treatment opportunity, optimize the healing path, summarize and promote the healing experience is a scientific problem to be solved urgently. In the past 10 years, Chinese experts have been in the forefront of the world in the exploration of clinical cure of chronic hepatitis B, and have made remarkable achievements in many large-scale clinical practices. "STARHB" is currently accepting the application of the third batch of project hospitals. 
|
关注官方微信 
